Sheena Aurora

Sheena Aurora

Company: Pain Eli Lilly

Job title: Medical Fellow Global Launch Leader

Bio:

Dr. Aurora received her medical degree from Christian Medical College in India. She interned at Wayne University in Detroit and completed her residency in Neurology at Henry Ford Hospital, also in Detroit. She then completed a fellowship in Headache and Neurophysiology at Henry Ford Hospital. Before coming to Lilly, she was Clinical Associate Professor of Neurology at Stanford University School of Medicine. She joined Lilly in April, 2016 as the Launch Leader for Galcanezumab. Dr. Aurora is board certified in neurology, headache management, and electro diagnostic medicine. She is an active member of several professional societies and has previously served as Chair of the American Academy of Neurology’s Headache Science Working Group; Co-Director of the American Headache Society’s Fall Symposium; and member of the Migraine Research Foundation’s Medical Advisory Board and the National Institute of Neurological Disorders and Stroke’s Working Group. She is also a former Secretary of the American Headache Society. Among Dr. Aurora’s many honors, she received the American Association for the Study of Headache’s Harold G. Wolff Award for Research in Headache (1999, 2001, 2007) and was selected to Seattle Magazine’s list of best doctors (2010, 2011, 2012 and on the list of best doctors in the San Francisco bay area 2015). Dr. Aurora has published more than 90 peer-reviewed manuscripts, most recently in The Journal of Pain, Headache, Acta Neurological Scandinavica, and Journal of Neurology, Neurosurgery, and Psychiatry. She was also one of the principal investigators of the first migraine program project funded by the National Institutes of Health. She lectures internationally on the topics of migraine, headaches, and pain. She continues to be an adjunct clinical associate professor in the Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University in California.

Seminars:

Discussing the Current Anti-CGRP Status & the Challenges & Opportunities They Pose 12:00 am - 2:00 pm

Read more

day: Day Two